Regeneron to Acquire 23andMe for $256M
Regeneron Pharmaceuticals has agreed to acquire 23andMe’s consumer genetics business and assets for $256 million, following 23andMe’s Chapter 11 bankruptcy.
More Videos
The Future of Fertility: How AI Is Transforming the Way Couples Conceive
Doctors report the first successful pregnancy using AI to find hidden sperm, marking a major fertility breakthrough, reports TIME’s Alice Park.
Go Fund Yourself: A New Safety Wearable + Making Solar Power More Accessible
Why iByte might save your life. Plus, how Energy ReLeaf is making solar power more accessible.
Trump Family Crypto Empire: A Web of Millions, Influence, and Ethical Concerns
Sam Blum, Senior Writer at Inc. Magazine, discusses one of his latest articles on why the Trump family is embracing crypto. Watch!
Real Assets Gain Traction in Bank of America's 2025 Specialty Asset Management Outlook
Ken Shepard, Head of Specialty Asset Management at Bank of America, discusses the importance of real assets and unpacks the bank's specialty asset outlook.
Cardinal Health Raises Pharmaceutical Segment Profit Guidance 12-13% for FY25
Cardinal Health's Debbie Weitzman explains how the company's Advanced Therapy Solutions Innovation Center aims to improve access to specialty medicines. Watch!
Inside the CRE Market: Peachtree Group CEO Breaks Down Industry Trends
Peachtree CEO Greg Friedman on the hospitality business, commercial real estate and what the numbers are telling you. Watch!
